

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptacmb1647

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

| | | | |
|------|----|--------|--|
| NEWS | 1 | | Web Page for STN Seminar Schedule - N. America |
| NEWS | 2 | AUG 06 | CAS REGISTRY enhanced with new experimental property tags |
| NEWS | 3 | AUG 06 | FSTA enhanced with new thesaurus edition |
| NEWS | 4 | AUG 13 | CA/Caplus enhanced with additional kind codes for granted patents |
| NEWS | 5 | AUG 20 | CA/Caplus enhanced with CAS indexing in pre-1907 records |
| NEWS | 6 | AUG 27 | Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB |
| NEWS | 7 | AUG 27 | USPATOLD now available on STN |
| NEWS | 8 | AUG 28 | CAS REGISTRY enhanced with additional experimental spectral property data |
| NEWS | 9 | SEP 07 | STN AnaVist, Version 2.0, now available with Derwent World Patents Index |
| NEWS | 10 | SEP 13 | FORIS renamed to SOFIS |
| NEWS | 11 | SEP 13 | INPADOCDB enhanced with monthly SDI frequency |
| NEWS | 12 | SEP 17 | CA/Caplus enhanced with printed CA page images from 1967-1998 |
| NEWS | 13 | SEP 17 | Caplus coverage extended to include traditional medicine patents |
| NEWS | 14 | SEP 24 | EMBASE, EMBAL, and LEMBASE reloaded with enhancements |
| NEWS | 15 | OCT 02 | CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt |
| NEWS | 16 | OCT 19 | BEILSTEIN updated with new compounds |
| NEWS | 17 | NOV 15 | Derwent Indian patent publication number format enhanced |
| NEWS | 18 | NOV 19 | WPIX enhanced with XML display format |
| NEWS | 19 | NOV 30 | ICSD reloaded with enhancements |
| NEWS | 20 | DEC 04 | LINPADOCDB now available on STN |
| NEWS | 21 | DEC 14 | BEILSTEIN pricing structure to change |
| NEWS | 22 | DEC 17 | USPATOLD added to additional database clusters |
| NEWS | 23 | DEC 17 | IMSDRUGCONF removed from database clusters and STN |
| NEWS | 24 | DEC 17 | DGENE now includes more than 10 million sequences |
| NEWS | 25 | DEC 17 | TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment |
| NEWS | 26 | DEC 17 | MEDLINE and LMEEDLINE updated with 2008 MeSH vocabulary |
| NEWS | 27 | DEC 17 | CA/Caplus enhanced with new custom IPC display formats |
| NEWS | 28 | DEC 17 | STN Viewer enhanced with full-text patent content from USPATOLD |
| NEWS | 29 | JAN 02 | STN pricing information for 2008 now available |
| NEWS | 30 | JAN 16 | CAS patent coverage enhanced to include exemplified prophetic substances |
| NEWS | 31 | JAN 28 | USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats |
| NEWS | 32 | JAN 28 | MARPAT searching enhanced |
| NEWS | 33 | JAN 28 | USGENE now provides USPTO sequence data within 3 days of publication |
| NEWS | 34 | JAN 28 | TOXCENTER enhanced with reloaded MEDLINE segment |

NEWS 35 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:10:39 ON 08 FEB 2008

=> file medline embase biosis caplus

'MEDLINE' IS NOT A VALID FILE NAME

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

ENTER A FILE NAME OR (IGNORE):medline

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|----------------------|------------------|---------------|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'MEDLINE' ENTERED AT 11:10:56 ON 08 FEB 2008

FILE 'EMBASE' ENTERED AT 11:10:56 ON 08 FEB 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:10:56 ON 08 FEB 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:10:56 ON 08 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s Lubeck(w)protocol or Luebeck(w)protocol

L1 5 LUBECK(W) PROTOCOL OR LUEBECK(W) PROTOCOL

=> dup rem l1

PROCESSING COMPLETED FOR L1

L2 2 DUP REM L1 (3 DUPLICATES REMOVED)

=> dis ibib abs l2 1-2

L2 ANSWER 1 OF 2 MEDLINE on STN DUPLICATE 1

ACCESSION NUMBER: 1998427993 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9755411

TITLE: New approaches to ovarian stimulation.

AUTHOR: Diedrich K; Felberbaum R

CORPORATE SOURCE: Department of Obstetrics and Gynecology, Medical University

of Lubeck, Germany.

SOURCE: Human reproduction (Oxford, England), (1998 Jun) Vol. 13
Suppl 3, pp. 1-13; discussion 14-7. Ref: 43
Journal code: 8701199. ISSN: 0268-1161.

PUB. COUNTRY: ENGLAND: United Kingdom

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 199811

ENTRY DATE: Entered STN: 6 Jan 1999
Last Updated on STN: 6 Jan 1999
Entered Medline: 17 Nov 1998

AB Suppression of endogenous hormone production by gonadotrophin-releasing hormone (GnRH) agonists followed by controlled ovarian hyperstimulation (COH) with human gonadotrophins, especially the so-called 'long protocol' has developed from second-line into first-line therapy. Due to this attitude premature luteinization can be safely avoided, enhancing therapeutic efficacy. Recombinant preparations of human follicle stimulating hormone (FSH) have been proven to be effective within COH according to the long protocol. The high purity of these compounds may have clinical advantages. GnRH antagonists could be successfully introduced in COH protocols. Also, daily injections in the midcycle phase according to the 'Lubeck protocol', as single or only dual administrations around day 9 seem to abolish any premature LH rises. Due to their different pharmacological mode of action, based on a classic competitive receptor blockage GnRH antagonists avoid any flare-up period and allow ovarian stimulation to start within the spontaneous cycle. Pregnancy rates are comparable to those after long protocol stimulation. Combination of softer stimulation regimes like clomiphene citrate and low dose HMG with midcycle administration of GnRH antagonists may be the way to a cheap, safe and efficient ovarian stimulation. It seems to be high time for modest forms of ovarian stimulation, lowering burden and risk for our patients.

L2 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:511666 CAPLUS

DOCUMENT NUMBER: 129:255149

TITLE: Multiple dose protocol for the administration of GnRH-antagonists in IVF: the "Lubeck-protocol"

AUTHOR(S): Felberbaum, R.; Diedrich, K.

CORPORATE SOURCE: Department of Obstetrics and Gynecology, Medical University of Lubeck (D), Germany

SOURCE: In Vitro Fertilization and Assisted Reproduction, Proceedings of the World Congress of in Vitro Fertilization and Assisted Reproduction, Vancouver, B. C., May 24-28, 1997 (1997), 397-404. Editor(s): Gomel, Victor; Leung, Peter C. K. Monduzzi Editore: Bologna, Italy.
CODEN: 66MRAP

DOCUMENT TYPE: Conference

LANGUAGE: English

AB Due to their different pharmacol. mode of action GnRH-antagonists are able to suppress serum-concns. of LH within hours. Instead of "down-regulation" and "desensitization" a classic competitive blockage of the GnRH-receptors on the cell-membrane of the gonadotrophic cells seems to take place. The "flare up", typical for agonistic GnRH-analogs is completely avoided. While the first generation of GnRH-antagonists caused important problems due to allergic reactions, which inhibited their clin. introduction, Cetrorelix and Ganirelix as representatives of the youngest generation of these compds. seem to avoid these disturbances completely.

Cetrorelix was introduced first in our IVF-program to scrutinize the possibility of avoiding premature LH-surges. All patients were treated with human menopausal gonadotropin (HMG), starting on day 2. From day 7 until induction of ovulation by human chorionic gonadotropin (HCG) Cetrorelix is administered s.c. in a daily fashion. Starting with a dosage of 3-mg Cetrorelix/day no premature LH-surges could be observed. Also, 1 mg/day, 0.5 mg/day and 0.25 mg/day administered according to the described "Lubeck-protocol" avoided any premature LH-surges. The mean courses of FSH and LH in the different dosage groups were quite similar with a profound suppression of LH. Estradiol concns. reflected a satisfactory follicular development. The fertilization-rate after IVF in cases of tubal infertility or ICSI in cases of male subfertility were within the range to be expected after normal oocyte maturation.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

15.05 15.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-0.80 -0.80

STN INTERNATIONAL LOGOFF AT 11:13:01 ON 08 FEB 2008